Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari Italy.
Department of Mechanical, Chemical and Materials Engineering, International Ph.D. In Innovation Sciences and Technologies, University of Cagliari, Cagliari Italy.
Expert Opin Investig Drugs. 2021 Nov;30(11):1081-1087. doi: 10.1080/13543784.2021.2000965. Epub 2021 Nov 29.
The quest toward more effective treatments for bipolar disorder (BD) solicits novel drugs and further research on the underpinning neurobiology. The present review aims to critically appraise the existing evidence about the pharmacological treatment of BD toward the development of novel treatment avenues.
The present review appraises animal and human studies concerning both the currently available psychotropic drugs, and the general medicine drugs which may represent a path toward the development of novel drugs for BD. PubMed and Scopus were last accessed on February 20, 2021 for records indexed upon inception relevant to the pharmacological treatment of BD. Immune-modulating agents, anti-inflammatory agents, and glutamate antagonists represent the most intriguing potential targets for the development of new drugs for BD, thus receiving critical appraisal in the present text.
Regardless of the neurobiological pathways worthy of investigation toward the development of experimental drugs for BD, several unmet needs need to be addressed first. In particular, several biomarkers are altered in BD. However, it is the opinion herein expressed by the authors that it remains uncertain what comes first, that is peripheral changes or the disease.
为了寻求更有效的双相情感障碍（BD）治疗方法，人们在不断探索新的药物，并进一步研究其潜在的神经生物学机制。本综述旨在批判性地评估目前关于 BD 药物治疗的现有证据，以期为新的治疗方法开辟途径。
本综述评估了涉及现有精神药物和一般医学药物的动物和人体研究，这些药物可能代表着开发 BD 新药物的途径。检索了 PubMed 和 Scopus 数据库，截至 2021 年 2 月 20 日，以获取有关 BD 药物治疗的索引记录。免疫调节剂、抗炎药和谷氨酸拮抗剂是 BD 新药开发最具吸引力的潜在靶点，因此在本文中进行了批判性评估。
无论对开发 BD 实验药物值得研究的神经生物学途径如何，首先都需要解决几个尚未满足的需求。特别是，BD 患者的几种生物标志物发生了改变。然而，作者在此表达的观点是，目前尚不清楚是外周变化还是疾病先出现。
